Olaparib increases chemosensitivity by upregulating miR-125a-3p in ovarian cancer cells.

ABSTRACT:

Objective

Ovarian cancer is associated with the highest mortality rate among all malignant gynecological tumors. PolyADP-ribose polymerase (PARP) inhibitor maintenance therapy is the standard treatment strategy for this type of cancer, and olaparib is a widely used oral PARP inhibitor for tumors with BRCA mutations. The present study aimed to investigate the effects of olaparib in non-BRCA-mutated ovarian cancer and the potential mechanisms involved.

Methods

The antitumor effect of cisplatin alone or in combination with olaparib was analyzed in an ovarian cancer subcutaneous transplantation tumor model in nude mice. Furthermore, the differences in microRNA (miRNA) expression levels were analyzed using miRNA arrays. In addition, the effects of miR-125a-3p on the proliferation

SUBMITTER: Wang Z 

PROVIDER: S-EPMC11893969 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature